Overview

Treatment for Achilles Tendinopathy

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether sclerotherapy using a 25% dextrose and 1% lidocaine solution is an efficacious treatment for patients with chronic Achilles tendinopathy who have failed a home based, heavy load eccentric training program.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Calgary
Collaborator:
Sport Science Association of Alberta (SSAA)
Treatments:
Lidocaine
Criteria
Inclusion Criteria:

- Adults 18 years of age and older with a minimum of 3 months of clinically determinant
history and symptoms (pain) consistent with unilateral Achilles tendinopathy
(enthesitis or mid-portion) as diagnosed by a sport medicine physician.

- Participants are not required to have tried other treatments, however, those who have
tried other treatments (except injection treatments) including, but not restricted to,
oral NSAIDs, topical NSAIDs, shoe modifications, and physical/athletic therapy will
not be restricted from the study

- Provide informed consent for the controlled longitudinal study and RCT

Exclusion Criteria:

- Individuals with physical ailments precluding them from performing the eccentric
training program

- Worker's Compensation Board (WCB) and elite athletes (varsity, national and
professional level).

- Individuals younger than 18 years of age will be excluded from this trial due to the
complicating factors of musculoskeletal immaturity and the lack of relevant research
of Achilles tendinopathy and neovascular bundles in this population.

- Previous Achilles tendon rupture of the tendon in question

- Individuals that have received any type of injection in or around the Achilles tendon

- Known allergy to dextrose based sclerosing agent or other contraindications

- Known allergy to Lidocaine